Qiagen (QGEN) said Monday it has entered into partnerships with Tracer Biotechnologies and Foresight Diagnostics to advance the use of minimal residual disease testing in clinical trials, specifically covering solid tumors and hematological cancers.

Qiagen said it is working with Tracer to create companion diagnostics for minimal residual disease testing in solid tumors, while its collaboration with Foresight involves a kit-based version of Clarity assay, a circulating tumor DNA-based next-generation sequencing test for certain types of lymphoma.

Price: 44.88, Change: -0.25, Percent Change: -0.56